299 related articles for article (PubMed ID: 26116769)
1. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
2. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.
Iwamaru A; Szymanski S; Iwado E; Aoki H; Yokoyama T; Fokt I; Hess K; Conrad C; Madden T; Sawaya R; Kondo S; Priebe W; Kondo Y
Oncogene; 2007 Apr; 26(17):2435-44. PubMed ID: 17043651
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
10. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
[TBL] [Abstract][Full Text] [Related]
11. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM
Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
Kawamata N; Chen J; Koeffler HP
Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
16. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.
Zhou X; Ren Y; Liu A; Han L; Zhang K; Li S; Li P; Li P; Kang C; Wang X; Zhang L
Oncol Rep; 2014 May; 31(5):2173-80. PubMed ID: 24676554
[TBL] [Abstract][Full Text] [Related]
17. STAT3 inhibitor WP1066 as a novel therapeutic agent for bCCI neuropathic pain rats.
Xue ZJ; Shen L; Wang ZY; Hui SY; Huang YG; Ma C
Brain Res; 2014 Oct; 1583():79-88. PubMed ID: 25084036
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
Chaturvedi NK; Hatch ND; Sutton GL; Kling M; Vose JM; Joshi SS
Leuk Lymphoma; 2019 May; 60(5):1214-1223. PubMed ID: 30424705
[TBL] [Abstract][Full Text] [Related]
19. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
Horiguchi A; Asano T; Kuroda K; Sato A; Asakuma J; Ito K; Hayakawa M; Sumitomo M; Asano T
Br J Cancer; 2010 May; 102(11):1592-9. PubMed ID: 20461084
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
Chiu HC; Chou DL; Huang CT; Lin WH; Lien TW; Yen KJ; Hsu JT
Biochem Pharmacol; 2011 Jun; 81(11):1263-70. PubMed ID: 21406185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]